TFA
SMMT icon

Toth Financial Advisory’s Summit Therapeutics SMMT Stock Holding History

Toth Financial Advisory’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$30.4K Buy
+1,800
New +$26.9K ﹤0.01% 448
2026
Q2 		– Sell
-90
Closed -$1.71K – 993
2026
Q1 		$1.71K Hold
90
– – ﹤0.01% 735
2025
Q4 		$1.57K Buy
+90
New +$1.69K ﹤0.01% 741

Other funds holding SMMT

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
MHR
Matthew Hamilton Rosenberg $558M AUM 12.28% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Toth Financial Advisory's SMMT Position: Q3 2026 in Review

Toth Financial Advisory opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 1,800 shares worth $30.4K. The stake represents ﹤0.01% of the portfolio and ranks #448 among its holdings. This is a return to the name: Toth Financial Advisory previously reported a position in SMMT as recently as Q1 2026.

Toth Financial Advisory first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Toth Financial Advisory held 1,800 shares of Summit Therapeutics worth $30.4K as of Q3 2026.
  • Summit Therapeutics was a new Toth Financial Advisory position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of Toth Financial Advisory's portfolio in Q3 2026, its #448 holding.
  • Toth Financial Advisory first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Toth Financial Advisory's 13F filing for Q3 2026, filed 8 Oct 2026.